Trial Profile
AN OPEN-LABEL, PARALLEL GROUP, SINGLE AND MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERATION OF MARAVIROC ADMINISTERED TO SUBJECTS WITH VARIOUS DEGREES OF RENAL IMPAIRED AND NORMAL RENAL FUNCTION
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2013
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Ritonavir; Saquinavir
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Pfizer
- 19 Dec 2012 New trial record